JVI Accepted Manuscript Posted Online 13 July 2016 J. Virol. doi:10.1128/JVI.01134-16 Copyright © 2016, American Society for Microbiology. All Rights Reserved.

1	High Throughput siRNA Screening Identifies Phosphatidylinositol 3-kinase Class
2	II Alpha as Important for Production of Human Cytomegalovirus Virions
3	
4	William S Polachek ^a , Hanan F Moshrif ^b , Michael Franti ^c , Donald M Coen ^a ,
5	Vattipally B Sreenu ^d , & Blair L Strang ^{a,b, #}
6	
7	Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical
8	School, Boston, USA ^a ; Institute of Infection & Immunity, St George's, University
9	of London, London, UK ^b ; Boehringer Ingelheim Pharmaceuticals Inc.,
10	Connecticut, USA ^c ; MRC-University of Glasgow Centre for Virus Research,
11	Glasgow, UK ^d
12	
13	Running Head: PI3K-C2A is important for HCMV replication
14	
15	#Address correspondence to Blair L Strang, bstrang@sgul.ac.uk
16	
17	WSP and BLS contributed equally to this work.
18	
19	No. of words in Abstract: 185
20	No. of words in Importance: 110
21	No. of words in Text: 7282

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

22 ABSTRACT

23

24 High throughput siRNA screening is a useful methodology to identify 25 cellular factors required for virus replication. Here we utilized a high throughput siRNA screen based on detection of a viral antigen by microscopy to interrogate 26 27 cellular protein kinases and phosphatases for their importance during human 28 cytomegalovirus (HCMV) replication, and identified the Class Ш 29 Phosphatidylinositol 3-kinase PI3K-C2A as being involved in HCMV replication. 30 Confirming this observation, infected cells treated with either pooled or individual 31 siRNAs targeting PI3K-C2A mRNA produced approximately 10-fold less 32 infectious virus compared to controls. Western blotting and quantitative PCR 33 analysis of infected cells treated with siRNAs indicated that depletion of PI3K-34 C2A slightly reduced accumulation of late, but not immediate-early or early, viral 35 antigens and had no appreciable effect of viral DNA synthesis. Analysis of siRNA 36 treated cells by electron microscopy and western blotting indicated that PI3K-37 C2A was not required for production of viral capsids, but did lead to increased 38 numbers of enveloped capsids in the cytoplasm that had undergone secondary 39 envelopment and reduction of viral particles exiting the cell. Therefore, PI3K-C2A 40 is a factor important for HCMV replication and has a role in production of HCMV 41 virions.

44

Accepted Manuscript Posted Online

Journal of Virology

There is limited information about the cellular factors required for human 45 cytomegalovirus (HCMV) replication. Therefore, to identify proteins involved in 46 47 HCMV replication we developed a methodology to conduct a high throughput 48 siRNA screen in HCMV infected cells. From our screening data we focused our 49 studies on the top "hit" from our screen, the lipid kinase phosphatidylinositol 3-50 kinase Class II Alpha (PI3K-C2A), as its role in HCMV replication was unknown. 51 Interestingly, we found that PI3K-C2A is important for the production of HCMV 52 virions and is involved in virion production after secondary envelopment of viral 53 capsids, the encapsidation of HCMV capsids by a lipid bilayer that occurs before 54 virions exit the cell.

55

 \leq

Journal of Virology

56 INTRODUCTION

57

58 Identification of factors encoded by the cell that are required for virus 59 replication can illuminate important features of virus-host interactions and identify novel drug targets for therapeutic intervention. Stages of productive human 60 61 cytomegalovirus (HCMV) replication takes place in both the nucleus and the 62 cytoplasm (1). After replication of the viral DNA genome in the nucleus, newly 63 synthesized viral genomic DNA is packaged into nascent capsids in the nucleus. 64 These capsids then bud through the nuclear membrane and, after accessing a viral assembly compartment in the cytoplasm (2), undergo a process of 65 66 "secondary envelopment" in the cytoplasm in which capsids gain a lipid bilayer 67 before exiting the cell (1). Many of these processes require the function of cellular factors, a number of which are unknown. 68

69 High throughput siRNA screening has been a successful strategy to 70 identify cellular factors important for replication of several viruses (3-9). Many of 71 the factors that have been identified by this strategy are kinases that are involved 72 in a diverse range of cellular processes (3-9). Cellular protein, nucleotide or lipid 73 kinases are involved in many aspects of HCMV replication (1). For example, 74 cellular protein kinases are involved in the intracellular signaling required for 75 activation of viral transcription (10, 11) and many other processes (1). The roles 76 of cellular nucleotide kinases in HCMV replication are less well characterized, but 77 are likely to be important for HCMV DNA synthesis as they are involved in 78 nucleotide metabolism. Another form of kinase protein that must be considered

Journal of Virology

Z

79 are lipid kinases, proteins that phosphorylate the inositol ring of 80 phosphatidylinositol (PtdIns). Only a few investigations have examined whether 81 lipid kinases are involved in HCMV replication. Class I Phosphatidylinositol 3-82 kinase (PI3K) is important for intracellular signaling involved in HCMV replication 83 (12) and class III PI3K Vps34 is required for secondary envelopment to occur 84 (13). However, the role of class II PI3K proteins in HCMV replication is unknown.

85 High throughput siRNA screens targeting human kinase and metabolic 86 proteins has been performed and have highlighted the involvement of many cellular proteins and pathways in HCMV replication, notably, the cellular 87 metabolic pathways involving 5'-AMP-activated protein kinase (AMPK) (8, 9). 88 89 However, studies of multiple siRNA screens against a common target 90 demonstrate that different siRNA screens can produce different outcomes due to 91 false positives, false negatives and the efficiency of siRNAs utilized in different 92 experiments (7). Therefore, it is possible that any number of kinase proteins that 93 are required for HCMV replication have yet to be identified.

To identify cellular kinases required for HCMV replication we developed a high throughput siRNA screen based on the detection of a viral antigen in infected cells by microscopy. From this screen, we found that several unrelated kinase proteins scored as hits, including the phosphatidylinositol 3-kinase Class II alpha protein (PI3K-C2A), which we examined further.

100 MATERIALS & METHODS

101

102 Cells and viruses. Human foreskin fibroblast (HFF) cells (clone Hs29) were 103 obtained from American Type Culture Collection no. CRL-1684 (ATCC, 104 Manassas, VA)). All cells were maintained in complete media: Dulbeccos 105 Modified Eagles Medium (DMEM) (Gibco) containing 5% fetal bovine serum 106 (FBS) (Gibco), plus penicillin and streptomycin. Unless indicated otherwise, 107 HCMV strain AD169 was used. HCMV strain Merlin(RCMV1111) (14) was a kind 108 gift from Richard Stanton (Cardiff University).

109

110 Transfection and infection of cells for high throughput screening. The 111 Dharmacon SMARTpool kinase-phosphatase collection (catalog number G-112 003500) comprises 789 siRNA targets (Table S1) and was screened in triplicate 113 at the ICCB-L facility at Harvard Medical School. Each pool contains 4 individual 114 siRNA. Twenty-four hours before transfection 1000 HFF cells were seeded in 115 each well of each Corning 384 plate in complete media with no antibiotics. 116 Unless stated otherwise, liquid was added to wells using a WellMate apparatus. 117 At the time of transfection, an intermediate plate (ThermoScientific 384 well plate 118 no.4309) was prepared to mix siRNA with lipid. Thus, 8.5 I of each siRNA at a 119 concentration of 1 M was added to the intermediate plate along with 7 I of 120 OptiMEM (Gibco). The intermediate plate was incubated at room temperature for 121 5 minutes. During this incubation period a lipid:OptiMEM mix was prepared 122 (0.17 | Dharmafect 2 lipid (Dharmacon) plus 11 | OptiMEM per well) and

123 incubated for no more than 5 mins at room temperature. 11.17 | of lipid:OptiMEM 124 mix was added to each well of the intermediate plate and incubated for a further 125 20 mins at room temperature. Media was removed from plates containing HFF 126 cells with a suction manifold and 8 I of siRNA:lipid mix from the intermediate 127 plate was added to triplicate plates using a liquid handling robot. To the 128 transfected cells 30 I of complete media without antibiotics was added to each 129 well. In each plate, wells used for 6 negative and 6 positive controls were 130 transfected with SMARTpool Non-targeting siRNA #3 (D-001810-03-05) or 131 SMARTpool Human PLK1 (M-003290-01), respectively. Where indicated individual PI3K-C2A SMARTpool siRNAs (LU-006771-00-0005) were used in 4 132 133 wells of a plate. Control and individual siRNAs were added to intermediate plates 134 by hand. Transfected cells were incubated for 72 hours at 37°C. Cells were then 135 infected with HCMV strain AD169 (MOI 1) in a total volume of 20 I for 2 hours at 136 37°C. The inoculum was removed and cells were incubated for a further 72 hours 137 at 37°C. Plates were then analyzed by microscopy to assess HCMV replication.

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

138

Preparation of screening plates for high throughput microscopy analysis. Cell culture media was removed from infected cells and replaced with 20 1 Hoecsht 33342 (SIGMA) diluted in phosphate buffered saline (PBS) to a final concentration of 10 g/ml. After incubation for 1 hour at 37°C, 20 1 of Deep Red CellMask (Invitrogen) (diluted in PBS to a concentration of 5 g/ml) was added to each well. Cells were incubated for a further 5 mins at 37°C. Cells were then fixed by removing PBS containing Hoescht and Cell Mask and adding 50 1 of

146 3.5% formaldyhyde (SIGMA) in PBS to each well. After incubating at room 147 temperature for 10 mins, fixative was removed and 50 I of PBS containing 0.5% 148 TritonX-100 was added per well to permeablize cells. After 10 mins incubation at 149 room temperature, PBS containing detergent was removed, and cells were 150 washed once with PBS. PBS was removed and replaced with 20 I MAb P207 151 recognizing pp28 (Virusys) (dilution 1:1000) and anti-mouse secondary antibody 152 conjugated to flurophore Alexa488 (Molecular Probes) (dilution 1:1000). Plates 153 were incubated at 37°C for 1 hour. After incubation, PBS containing antibodies 154 was removed and replaced with 50 I of PBS. Plates were then analyzed by 155 microscopy.

156

157 **Microscopy analysis of screening plates.** Infected cells stained with antibody 158 to detect pp28 were imaged on an Image Express Micro (IXM) microscope 159 (Molecular Devices) at 10x magnification to detect 3 wavelengths; 488 nm to 160 detect antibody recognizing pp28, 568nm to detect Deep Red CellMask and 350 161 nm to detect Hoescht 33342 stain bound to DNA. Three images were captured 162 from each wavelength in each well of 384-well plates. The number of cells 163 positive for all 3 wavelengths and percentage of pp28 positive cells in each well 164 was determined by analyzing the presence of signal from each wavelength using 165 the Metamorph Multiwavelength Cell Scoring software (Molecular Devices). 166 Typically, the average number of pp28 positive cells found when cells were 167 treated with non-targeting siRNA was 30-40% (data not shown).

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

168

Journal of Virology

Analysis of screening results. To assess the quality of data that could be returned from the screening protocol we calculated the *Z*'-factor (15, 16) derived from the positive (PLK1 siRNA treated infected cells) and negative (Non-targeting siRNA #3 infected cells) controls. The screening controls returned *Z*'-factors of greater than or equal to 0.5, indicating a robust separation of difference in the data derived from positive and negative controls. Thus, the screening protocol could be reliably used to screen the siRNA collection.

176 After screening of the siRNA collection data was analyzed to address 177 siRNA cytotoxicity. siRNAs were judged to have a cytotoxic effect when the number of cells stained with Hoescht 33342 in a well fell below 2-fold of the 178 179 mean of the number of cells in each well of the plate. Data from those wells 180 containing cytotoxic siRNA was discarded. The data from the remaining wells 181 from each plate was converted to a z-score (15, 16) and the average z-score 182 from data in triplicate plates was determined. Images chosen at random were 183 visually inspected throughout image capture and analysis to ensure raw data was 184 consistent with z-scores.

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

185

GESS and Haystack analysis of siRNA binding. The on-line version of GESS (17, 18) was used. For Haystack (19) analysis of top screening "hits", Haystack was downloaded from http://rnai.nih.gov/haystack/. siRNA sequences were compared to 3' untranslated regions (3' UTRs) of human mRNA provided by Haystack. A list of viral 3'UTRs (300 nucleotides) was generated from the HCMV

Journal of Virology

AD169 genome and compared to siRNA sequences. All siRNA sequences were 191

192 supplied by Dharmacon.

193

194 Kinase inhibitors. Compound C was purchased from Merck, and resuspended 195 in dimethyl sulfoxide (DMSO).

196

197 Preparation of cell lysates for western blotting. In experiments to detect PI3K-C2A, 1x10⁵ HFF cells were washed twice with ice cold PBS and 198 199 immediately scraped into 100 ml of lysis buffer (50 mM Trizma, 150 mM NaCl, 200 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 10% glycerol, 1 mM 201 sodium fluoride, 2.5 mM sodium pyrophosphate, 50 mM β-glycerophosphate, 1 202 mmol/L sodium orthovanadate, 40 mg/L phenylmethylsulfonyl fluoride, plus 1 203 Halt Protease Inhibitor tablet (ThermoSci #1860932)/100ml). Lysate was 204 incubated on ice for 30 mins, then centrifuged for 5 mins at 12,700 rpm. 205 Supernatant was removed and diluted 1:1 in 2x Laemmli buffer containing 5% β -206 mercaptoethanol. Samples were incubated to 60°C for 10 mins.

207 All other samples were prepared for western blotting by washing cells 208 once in PBS, the suspending cells directly in 2x Laemmli buffer containing 5% β-209 mercaptoethanol before incubating at 95°C for 5 mins.

210

211 Western blotting. Western blotting of proteins separated on 8% or 10% or 212 polyacrylamide gels was carried out as described elsewhere (20), using 213 antibodies recognizing IE1/2, UL44, pp28, (all Virusys, 1:1000 dilution), β-actin 214 (SIGMA, 1:5000 dilution), UL86 (a kind gift from Wade Gibson, Johns Hopkins 215 University, 1:1000 dilution), gB (F3-11E, from the NIH AIDS Reagents Program, 216 1:1000 dilution) and PI3K-C2A (BD Bioscience #611046, 1:1000 dilution). All primary antibodies were incubated overnight at 4°C and detected using anti-217 218 mouse- or anti-rabbit-horseradish peroxidase (HRP) conjugated antibodies (Southern Biotech). Chemiluminescence solution (GE Healthcare) (or when 219 220 assaying for PI3K-C2A, Fempto detection reagent (Thermo)) were used to detect 221 secondary antibodies on film. Where indicated in the text, relative band 222 intensities were calculated using ImageJ software provided by the National 223 Institutes of Health, USA.

224

Transfection of siRNA into HFF cells. Briefly, 1 x 10⁵ HFF per well were 225 226 seeded in 12-well plates 24 hours before transfection in DMEM+5%FBS with no 227 antibiotics. Per well, 113 µl of 1 µM siRNA and 2 µl Dharmafect2 (Dharmacon) 228 were diluted in 93 µl and 146 µl Optimem (Invitrogen), respectively. After 5 mins 229 at room temperature, both solutions were combined. After 20 mins, media was 230 removed from each well and replaced with the siRNA/Dharmafect mixture and 231 500 µl of DMEM+5%FBS with no antibiotics was added to each well. Transfected cells were incubated at 37°C for 72 hours then either prepared for western 232 blotting or infected with 1×10^5 plaque forming units (p.f.u./ml) of AD169. 233

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

234

Determination of viral titer. Titers were determined by serial dilution of viral
supernatant onto HFF monolayers which were then covered in DMEM containing

5% FBS and 0.6% methylcellulose. Cultures were incubated for 14 days, cells
were stained with crystal violet and plaques were counted.

239 Real time quantitative PCR analysis of viral DNA synthesis in siRNA treated 240 cells. HFF cells were treated with siRNA and infected as outlined above in 241 triplicate. DNA was isolated from infected cells using the NucleoSpin Tissue Kit 242 (Macherey-Nagel) according to the manufacturer's instructions. Viral genomes 243 were quantified with a primer pair (pp549s and pp812as) to UL83 (21) and the 244 number of viral genomes was normalized to cellular copies of adipsin (22). 245 Unknown sample values were determined on the basis of standard curves of 246 known copy numbers of UL83 (pcDNAUL83, a kind gift from Jeremy Kamil, 247 Louisiana State University) and adipsin (from uninfected cell DNA). PCRs for 248 UL83 and adipsin were carried out on a BioRadCFX96 machine using 249 SsoAdvanced[™] Universal SYBR[®] Green Supermix (BioRad) as per the 250 manufacturer's instructions. Linear regression analysis of UL83 and adipsin standards in triplicate yielded R² values of 0.997 and 0.996. The mean number of 251 252 copies of the viral gene UL83 per copy of the cellular gene adipsin was 253 calculated from the triplicate samples assayed.

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

254

Immunofluorescence. 5x10⁴ HFF cells were plated on glass coverslips. Cells were uninfected or infected with AD169 (MOI 1). Cells were fixed in ice-cold methanol at time points indicated in the text. After washing in Dulbecco's phosphate-buffered saline (DPBS), samples were permeabilized with 0.1% Triton X-100 dissolved in DPBS at room temperature (RT) for 10 min. The cells were

260 washed again with DPBS and incubated in 1% bovine serum albumin (BSA) 261 dissolved in DPBS for 1 h at RT. Primary antibodies in 0.5% BSA dissolved in 262 DPBS were applied and incubated for 1 h at 37°C. Antiserum was removed by 263 washing cells once in 0.5% Tween dissolved in DPBS and twice with DPBS, each 264 time for 5 min with rocking. This procedure was repeated for the secondary 265 antibodies. DAPI (4',6-diamidino-2-phenylindole) was applied in the last 10 min of 266 the secondary antibody incubation. Coverslips were mounted on microscope 267 slides with ProLong Antifade (Invitrogen-Molecular Probes). All imaging 268 experiments were performed at the Nikon Imaging Center at Harvard Medical 269 School, using a Nikon Ti microscope with a spinning disk confocal laser at a 270 magnification of ×100. Images shown were obtained by acquiring sequential 271 optical planes in the z axis, using the MetaMorph program.

All primary antibodies recognizing UL53 (23) or PI3K-C2A (BD Bioscience #611046) were used at a dilution of 1:100. All fluorescently labeled secondary antibodies (Alexa Fluor 488 or Alexa Fluor 594) were obtained from Molecular Probes and used at a dilution of 1:1000.

276

Electron Microscopy. Cells were transfected with siRNA and infected as outlined above. Infected cells were incubated for 1 hour at room temperature in fixative (2.5% glutaraldehyde 1.25% paraformaldehyde and 0.03% picric acid in 0.1 M sodium cacodylate buffer (pH 7.4)) at the indicated time points post infection. Cells were provided to the Harvard Medical School Electron Microscope Facility and washed in 0.1M sodium cacodylate buffer (pH 7.4), then

Journal of Virology

lournal of Virology

283 postfixed for 30 min in 1% Osmium tetroxide (OsO4)/1.5% potassium 284 ferrocyanide (KFeCN), washed in water 3x and incubated in 1% aqueous uranyl 285 acetate for 30min followed by 2 washes in water and subsequent dehydration in 286 ethanol (5min each; 50%, 70%, 95%, 2x 100%). Cells were removed from the 287 dish in propyleneoxide, pelleted at 3000 rpm for 3 min and infiltrated for 2hrs in a 288 1:1 mixture of propyleneoxide and TAAB Epon (Marivac Canada Inc. St. Laurent, 289 Canada). The samples were subsequently embedded in TAAB Epon and 290 polymerized at 60°C for 48 hrs. Ultrathin sections (about 60nm) were cut on a 291 Reichert Ultracut-S microtome, picked up on to copper grids stained with lead 292 citrate. All samples were examined and images were recorded using a JEOL 293 1200EX Transmission electron microscope and an AMT 2k CCD camera, 294 respectively.

295

296 Preparation of virions from siRNA treated cells for western blotting. HFF 297 cells were transfected with either Ctrl or PI3K-C2A siRNA and infected as 298 outlined above. At 96 hours post infection viral supernatant from four Ctrl or four 299 PI3K-C2A siRNA transfections was collected (4ml in total). Supernatants were 300 clarified by centrifugation (13,000g, 5 mins, 4°C) to remove cells and cell debris. 301 Virions were then pelleted from supernatants by ultracentrifugation (20,000rpm, 1 302 hour, 4°C). Pellets were resuspended in 20 I of phosphate buffered saline 303 (Gibco). To test for protection from protease digestion, ten I of each 304 resuspended pellet was mixed with 10 I of trypsin (Gibco) and incubated for 1 305 hour at either 4°C or 37°C. After incubation, 20 I of 2x Laemmli buffer containing

- 306 5% β -mercaptoethanol was added to each samples and incubated at 95°C for 5
- 307 mins. For each western blot, 10 I of each sample was analyzed.

308

309

 $\overline{\leq}$

311

312 Development of a high throughput screening methodology. To 313 identify siRNAs that can affect HCMV replication, we sought to develop a high throughput screening methodology. In our initial studies, we attempted to 314 315 establish a screen in which plates of cells were treated with siRNAs and infected 316 with viruses expressing reporters such as green fluorescent protein (GFP) or 317 luciferase (data not shown). However, we found that reporter expression was not 318 sufficient to be readily detected in our assay (data not shown) and we found 319 considerable well-to-well variation in the numbers of GFP positive cells, which 320 may be due, in part, to production of particles that initiate abortive infections. 321 These issues were found in all cell lines tested including human foreskin 322 fibroblasts (HFFs) and U373-MG cells, where additional issues arose due to at 323 least ten-fold lower titers (data not shown). Therefore, we chose not pursue a 324 screen based on detection of a reporter protein expressed from a recombinant 325 HCMV virus. Instead, we decided to establish an automated high throughput 326 screening methodology based on the detection of a viral antigen by microscopy, 327 similar to siRNA screens created by Koyuncu and co-workers or Brass and co-328 workers to interrogate what cellular factors are required for replication of HCMV 329 and a variety of other viruses (3-7, 9). In preliminary experiments we found that 330 antibody staining of HFF cells to detect that viral antigen pp28 was a convenient, 331 reproducible and statistically robust methodology to detect HCMV replication 332 that, unlike our preliminary experiments, could be readily detected and did not

Accepted Manuscript Posted Online

Z

exhibit well-to-well variation that would make data interpretation problematic. As
pp28 is expressed late in infection, this allowed our screen to identify factors
affecting all stages of virus replication through to late gene expression, including
virus attachment, entry, transcriptional activation and genome replication.

337

338 High throughput screening of siRNAs. We then carried out an siRNA 339 screen, as outlined in Fig. 1A. Briefly, human foreskin fibroblasts (HFFs) were 340 transfected in triplicate with siRNAs from the Dharmacon kinase-phosphatase 341 collection (listed in Table S1). This collection of 779 pools of 4 siRNA targets 342 mRNA encoding kinases (including nearly all protein kinases, 7 nucleoside 343 kinases and 15 lipid kinases) and kinase related proteins (including 9 dual 344 specificity phosphatases and proteins that interact with kinases, such as CD4). 345 As negative and positive controls for siRNA treatment 6 wells in each plate were 346 treated with either Dharmacon non-targeting siRNA #3 (Crtl siRNA) or siRNA 347 targeting *polo-like kinase 1* (PLK-1) mRNA, respectively. PLK-1 is routinely used 348 as a positive control in siRNA screening as depletion of PLK-1 induces 349 apoptosis. Under conditions used here we found that treatment with PLK-1 350 siRNA inhibits HCMV replication without a statistically significant decrease in the 351 number of cells per well. Thus, even though this treatment is cytotoxic, it fulfilled 352 the conditions of the screen to serve as a positive control (see Materials & 353 Methods and below). Each control and screened siRNA used contained a pool of 354 4 individual siRNAs. HFF were incubated with siRNA for 72 hours. In preliminary 355 experiments 72 hour incubation was required to deplete proteins to near

356 undetectable levels by western blotting after treatment with a number of siRNAs 357 in the Dharmacon kinase-phosphatase collection (data not shown and Figs. 3A 358 and 3C). After incubation, siRNA transfected HFF cells were infected with HCMV 359 strain AD169 at a multiplicity of infection of 1 (MOI1). In preliminary experiments 360 this MOI provided the most statistically robust data (data not shown). At 72 hours 361 post infection (h.p.i.) cells were stained with Hoescht 33342 to detect nuclear 362 DNA and CellMask to identify the cell cytoplasm, plus treated with antibodies to 363 detect pp28. An automated microscopy system was then used to assay the 364 number of cells in each well and the number of cells containing pp28. An image 365 of infected cells treated as described above and captured using automated 366 microscopy is shown in Figure 1B. DNA and cells stained with Hoescht 33342 367 and CellMask are shown in blue and red, respectively. The cytoplasmic 368 localization of pp28 in viral assembly compartments is shown in green.

369 We then processed the screening data. Specifically, the mean number of 370 cells in each well per plate was determined by counting the number of Hoechst 371 stained nuclei. Where the number of cells in any well was less than 2-fold below 372 the mean number of cells of the plate, the siRNA in that well was judged to be 373 grossly cytotoxic. Five hundred and seventy two siRNAs (listed in Table S2) did 374 not pass this test and were not analyzed further. Data from the remaining 207 375 wells on triplicate plates were converted to a z-score (the number of standard 376 deviations from the mean of the data (15, 16)) to demonstrate the positive or 377 negative effect of siRNA on the number of pp28 positive cells detected. These

Journal of Virology

lournal of Virology

data were then combined to find the mean z-score of each pool of siRNA (Fig. 378 379 1C and listed in Table S3).

380

381 Analysis of siRNA that have positive and negative effects on HCMV 382 replication. We adjudged any siRNA that produced a z-score between 1 to -1 to 383 have had little or no effect on HCMV replication, whereas those with z-scores of -384 1 to -2 and 1 to 2 had modest negative or positive effects on HCMV replication, 385 respectively. However, siRNAs with z-scores of less than -2 or more than 2 were 386 deemed to have strong negative or positive effects on HCMV replication, 387 respectively. Twenty five siRNAs were found to have modest positive effects on 388 HCMV replication and 26 siRNAs had modest negative effects on HCMV 389 replication. No siRNA was found to have a strong positive effect on HCMV 390 replication, whereas 4 siRNAs (siRNAs targeting mRNA encoding PI3K-C2A, 391 CD4, EXOSC10 and WNK4) had strong negative effects on HCMV replication 392 (Fig. 1C and listed in Table S3).

393

394 Bioinformatics analysis of siRNA screening results to assay for off-395 target effects of siRNA treatment. False positive results can be found in siRNA 396 screens due to off-target binding of siRNAs. Off-target siRNA binding is most 397 likely to occur in the 3' untranslated region (3' UTR) of mRNA (24, 25) where 398 siRNA exhibit microRNA-like properties upon binding of a limited number of 399 bases, akin to a microRNA seed region, to mRNA (24-26). Indeed, it has been 400 proposed that the data returned from some screens is the result of unintentional

401 screening of partial seed sequence matches and not on-target binding of siRNA 402 (26). Therefore, using genome-wide enrichment of seed sequences matches 403 (GESS) (17, 18) we investigated if the siRNAs screened in this study (all 4 404 siRNAs that constitute the pools of siRNAs used) are enriched with seed 405 sequences that could bind either human 3'UTRs or full human mRNA transcripts. 406 We found no statistical evidence that siRNAs screened here are enriched with 407 seed sequences that would bind to any human mRNA sequence (data not 408 shown). The binding of siRNA to the sequence of the entire HCMV AD169 409 genome was also assayed and it was found that there was no statistically 410 significant evidence for enrichment of seed sequences in the siRNAs assayed 411 that would bind to any sequence in the viral genome (data not shown).

We sought to confirm this analysis by analyzing the binding of siRNAs from the top 4 "hits" from our screen (siRNAs targeting mRNA encoding PI3K-C2A, CD4, EXOSC10 and WNK4, Fig.1C) using Haystack (19), another bioinfomatic analysis that searches for statistically significant matches of siRNA sequences with 3'UTR transcripts. We found no statistically significant matches between the siRNAs tested with human or HCMV 3'UTRs (data not shown). Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

Therefore, the effects of siRNAs judged to be toxic or have negative or positive effects on HCMV replication in our analysis may not be be due to off target binding of siRNA seed matches to human or HCMV mRNA transcripts.

421 We then compared hits with z-scores of less than -1 and greater than 1 to 422 a proteomic dataset that lists all viral and cellular proteins detected in HCMV 423 infected HFF cells (27) (Table S4). We found that a number of proteins

purportedly depleted by siRNAs in our screen were not found in HCMV infected
HFF cells (8 of 30 hits and 12 of 25 hits with negative and positive effects of
HCMV replication, respectively.) Therefore, although GESS and Haystack
indicates that off-target siRNA binding does not occur, several false positives in
our screening data could be identified.

429

430 PI3K-C2A siRNAs deplete PI3K-C2A and specifically reduce numbers 431 of pp28-infected cells. We then chose to focus our studies on one of the top 432 "hits" in our screen. PI3K-C2A and EXOSC10, but not CD4 or WNK4, have been 433 found in HFF cells infected with HCMV (27) (Table S4). Therefore, CD4 and 434 WNK4 were excluded from further analysis. siRNAs targeting PI3K-C2A mRNA 435 had the greatest negative effect in our screen, and a role for PI3K-C2A in HCMV replication had not, to our knowledge, been previously reported. We, therefore, 436 437 decided to focus on the role of PI3K-C2A in HCMV replication. We first examined 438 the effects of each of the 4 individual PI3K-C2A siRNAs (PI3KC2A-1 to -4) from 439 the PI3K-C2A siRNA pool was tested for its ability to inhibit HCMV replication by 440 assaying cell number and pp28 expression using the scheme shown in Fig. 1A. 441 Compared to cells treated with Ctrl siRNA, treatment of cells with each PI3K-C2A 442 siRNA had no statistically significant effect on cell number (+/- 10% of DMSO 443 control, Fig. 2A) and resulted in a statistically significant decrease in the number 444 of pp28 expressing cells by at least 45% (Fig. 2B). This confirmed that PI3K-C2A 445 is involved in HCMV replication and implied that the effect of the PI3K-C2A

Journal of Virology

446

siRNA pool used in our screen was due to depletion of PI3K-C2A, not result of an 447 off-target effect of any one siRNA in the siRNA pool. 448 449 Effect of PI3K-C2A siRNA on production of infectious HCMV. We then

450 assayed the effects of PI3K-C2A siRNA on production of infectious virus. HFF cells were treated with either Ctrl siRNA, PI3K-C2A siRNA or the 4 individual 451 452 PI3K-C2A siRNAs from the PI3K-C2A siRNA pool (PI3KC2A-1 to -4) and infected 453 with HCMV. At various time points, supernatants were collected for titration of 454 infectious virus and infected cells were prepared for western blotting. Compared to treatment of cells with Ctrl siRNA, treatment of cells with PI3K-C2A siRNA or 455 456 individual PI3K-C2A siRNAs resulted in a clear decrease in accumulation of 457 PI3K-C2A in infected cells (Figs. 3A and 3C), and a decrease in production of 458 infectious virus over time (9- and 7-fold with PI3K-C2A at 72-96 h.p.i., 459 respectively, and 3- to 12-fold with individual siRNAs, Figs. 3B and 3D, 460 respectively). In these and subsequent western blots the amount of β -actin in 461 each sample was also assayed, which demonstrated equivalent loading of 462 samples in each lane. Therefore, depletion of PI3K-C2A in infected cells was 463 associated with a defect in the production of infectious HCMV virus. Also, a 464 decrease in production of virus from siRNA treated cells similar to that seen in 465 Figure 3B was observed from HFF cells treated with either Ctrl or PI3K-C2A 466 siRNA when infected with HCMV strain Merlin (data not shown). Thus, PI3K-C2A 467 is required for replication of at least two different HCMV strains.

469

470

471 the loss of PI3K-C2A. Therefore, western blotting was used to analyze the 472 accumulation of immediate-early (IE1/IE2), early (UL44) and late (pp28) HCMV 473 proteins and PI3K-C2A in lysate of HFF cells treated with either Ctrl or PI3K-C2A 474 siRNA and infected with HCMV (Fig. 4). Treatment of HFF cells with PI3K-C2A 475 siRNA resulted in a loss of PI3K-C2A accumulation in HCMV infected cells (Fig. 476 4A). However, we found no obvious difference in the accumulation of any viral 477 protein (Fig. 4A). We reasoned that this may be due to high levels of protein produced late in virus replication saturating the signal from our western blots. 478 479 Therefore, we created dilution series from the samples taken at 72 and 96 h.p.i. 480 in Figure 4A and subjected these samples to western blotting (Fig. 4B). We found no obvious difference in accumulation of either IE1/2 or UL44. However, 481 482 consistent with the data in Figures 1 and 3, we observed a ~2-fold difference in 483 accumulation of pp28 in cells treated with PI3K-C2A siRNA compared to Ctrl 484 siRNA (Fig. 4B). A similar reduction in the expression of the late viral antigen 485 UL86 was observed (data not shown). However, loss of viral production (Fig. 3) 486 in the presence of PI3K-C2A siRNA is greater than the modest decrease in pp28 487 expression that we observe in Fig. 4B. Therefore, depletion of PI3K-C2A is likely 488 to inhibit the production or function of viral or cellular factors important for 489 productive replication other than pp28.

Examination of viral protein and DNA production in cells treated with

siRNA. We next sought to understand how HCMV replication was inhibited by

490 As HCMV late gene expression is related to viral DNA synthesis (1), we 491 hypothesized that a decrease in pp28 protein might reflect a defect in genome

492 replication. Therefore, we treated HFF with Ctrl or PI3K-C2A siRNA and after 493 infection used quantitative real-time PCR to assay the number of HCMV 494 genomes in infected cells at 72 h.p.i. The number of viral genomes present in 495 each Ctrl or PI3K-C2A siRNA treated sample was determined by normalizing the 496 copy number of a viral locus (UL83) to the copy number of a cellular locus 497 (adipsin). We found no obvious decrease in the accumulation of viral DNA 498 between infected cells that had been treated with either Ctrl or PI3K-C2A siRNA 499 (1100 and 1200 copies UL83/copies adipsin, respectively). Therefore, the defect 500 in virus replication and loss of pp28 expression in the absence of PI3K-C2A was 501 unlikely to be due to a defect in viral DNA replication.

502

503 Analysis of HCMV capsid and virion production in cells treated with 504 PI3K-C2A siRNA. We then employed electron microscopy (EM) analysis to 505 further investigate how PI3K-C2A is involved in HCMV replication. We treated 506 cells with either Ctrl or PI3K-C2A siRNA and after infection submitted cells for 507 EM analysis and counted the number of viral capsids present in the nucleus and 508 cytoplasm in whole cell sections of five cells (Figs. 5A and 5B, respectively). 509 HCMV capsids can be found in 3 forms: A capsids; nonproductive forms thought 510 to result from failed packaging of viral genomes, B capsids; forms that contain a 511 scaffolding protein but no DNA, and C capsids; assembled forms in which the 512 scaffolding protein has been removed and replaced with viral DNA. We, 513 therefore, also counted the number of each form of HCMV capsid found in siRNA 514 treated cells (Fig 5A and 5B). In both Ctrl and PI3K-C2A siRNA treated cells

Journal of Virology

approximately 3-fold more capsids were found in the nucleus compared to the cytoplasm and we found no obvious difference in the number of any form of the HCMV capsid in either the nucleus or the cytoplasm. Therefore, the loss of PI3K-C2A did not affect the production of capsids, including genome containing C capsids that lead to infectious virions, or the movement of capsids from the nucleus to the cytoplasm.

521 However, compared to cells treated with Ctrl siRNA, we noted that in cells 522 treated with PI3K-C2A siRNA there was an ~3-fold increase in the number of 523 cytoplasmic capsids surrounded by lipid bilayer envelopes in the cytoplasm (Fig. 524 5C). Such particles are thought to have undergone secondary envelopment, a 525 late step in virion maturation prior to egress from the cell. Examples of such 526 enveloped capsids in cells treated with PI3K-C2A siRNA are shown in Fig. 5E(i)). 527 Therefore, depletion of PI3K-C2A produced an accumulation of capsids that had 528 undergone secondary envelopment in the cytoplasm, which may reflect a defect 529 in the ability of these particles to egress from the cell.

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

We noted that in our EM analysis more extracellular virions leaving the cell were found in cells treated with Ctrl siRNA compared to those treated with PI3K-C2A siRNA (Fig. 5D). An example of a virion leaving a cell treated with Ctrl siRNA is shown in Fig. 5E(ii). Although this difference was not statistically significant there was a clear trend toward a defect in virion production upon PI3K-C2A depletion. A confounding factor in this analysis could be that it does not account for the number of virions that have left infected cells. 537

538 western blotting to assay the presence of virion proteins in supernatant from 539 infected cells that had been treated with either Ctrl or PI3K-C2A siRNA (Fig. 5F). 540 Viral supernatants were collected and to remove cells and cellular debris 541 supernatants were first clarified with low speed centrifugation. Virions were then 542 pelleted using ultracentrifugation and pellets were treated with trypsin to remove 543 protein not protected by virion membranes. Thus, HCMV glycoprotein gB which 544 is found on the exterior of virions, on cells or in cell debris or shed into the 545 supernatant could be found in the samples treated with trypsin at 4°C (Fig. 5F, 546 lanes 1 and 3), but not 37°C (Fig. 5F, lanes 2 and 4). The similar amounts of gB 547 found in the supernatant of cells treated with either Ctrl or PI3K-C2A siRNA is 548 consistent with our observations from Figure 4, wherein depletion of PI3K-C2A 549 has only a modest effect on production of late viral proteins. The major HCMV 550 virion protein UL86, which is a component of virions and protected from trypsin 551 digestion by the virion membrane, was found in all samples. However, notably 552 less UL86 was found pellets from cells treated with PI3K-C2A siRNA (Fig. 5F, 553 lanes 3 and 4) compared to cells treated with Ctrl siRNA (Fig. 5F, lanes 1 and 2). 554 Using ImageJ software we found a 4-fold (Fig. 5F, lanes 1 and 3) and 9-fold (Fig. 555 5F, lanes 2 and 4) decrease in relative band intensity of UL86 blots of samples treated a 4°C and 37°C, respectively. Therefore, consistent with data presented 556 557 in Figs. 5A-5E, depletion of PI3K-C2A was associated with a defect in virion 558 production from infected cells.

To further investigate virion production from infected cells we used

Journal of Virology

Σ

559	The accumulation of capsids that have undergone secondary
560	envelopment and a lack of virion production inferred that there was an
561	accumulation of infectious intracellular virus in infected cells treated with PI3K-
562	C2A. We examined this possibility by treating cells with Ctrl or PI3K-C2A siRNA
563	and, after infection, assaying the amount of infectious virus released from
564	infected cells and the amount of intracellular virus at 96 h.p.i To release
565	intracellular virus infected cells were lysed by three sequential freeze/thaw cycles
566	to -80 $^{\circ}\text{C}.$ In cells treated with Ctrl or PI3K-C2A siRNA we observed a 10-fold
567	decrease in titre of infectious virus released from infected cells $(8 x 10^5 \mbox{ and } 8 x 10^4$
568	p.f.u./ml, respectively) and a less than a 2-fold difference in the amount of
569	infectious intracellular virus produced $(1x10^3 \text{ and } 2x10^3 \text{ p.f.u./ml, respectively})$.
570	Similar results were observed when infected cells were lysed by passing cells
571	three times through a needle (data not shown). Therefore, we found no obvious
572	increase in the amount of infectious intracellular virus in infected cells treated
573	with PI3K-C2A siRNA, which implied that the capsids that had undergone
574	secondary envelopment in infected cells treated with PI3K-C2A siRNA were not
575	infectious.

Journal of Virology

576 **DISCUSSION**

577

578 Here we provide a further demonstration that high throughput screening of 579 siRNAs is a valid methodology to identify cellular factors required for viral 580 replication. We identified a range of cellular kinase proteins involved in HCMV replication and focused our studies on how PI3K-C2A might be required for 581 582 HCMV replication. These studies indicated that PI3K-C2A is involved in 583 production of late viral proteins and production of infectious virus. However, in 584 infected cells treated with PI3K-C2A siRNA we observed a greater defect in 585 virion production compared to viral protein production. Thus, PI3K-C2A most 586 likely plays a more prominent role in the production of infectious HCMV virions, 587 than the production of HCMV proteins. Our data indicates that PI3K-C2A is 588 involved in processes that lead to egress from the cell of capsids that have 589 undergone secondary envelopment.

590 Our screening methodology allows us to survey siRNAs that affect nearly 591 all facets of HCMV replication and, as we demonstrate here, we can identify 592 siRNAs that have a fairly modest effect on pp28 expression, but a greater effect 593 on virus replication. An added advantage is that the cytoplasmic localization of 594 pp28 in viral assembly compartments can be dictated by the virally encoded 595 kinase UL97 (28), which is required for function of known anti-HCMV drugs (29) 596 and is itself a major drug target (30). Therefore, in future experiments our 597 methodology can be converted to a high throughput/high content screening 598 approach wherein the number of pp28 positive cells and localization of pp28

599 within infected cells can identify factors affecting UL97 function and assembly 600 compartment morphology. Conversely, this screening approach does not allow 601 us to assess to what degree any protein is depleted by siRNA within the screen 602 and the use of antibodies to detect viral replication limits the screen to only the 603 detection of HCMV replication. Furthermore, the MOI1 infections used during the 604 screening process typically result in 30-40% of cells infected in wells treated with 605 Ctrl siRNA (data not shown). Therefore, the transfection process may limit HCMV 606 infection and further optimization of our methodology may be required.

607 In our screen depletion of a range of kinase proteins had positive or 608 negative effects on HCMV replication. Each of these proteins may act alone or in 609 concert with other factors to facilitate HCMV replication. No phosphatase proteins 610 were found to have any effect. Identification of pathways involved in viral 611 replication has been possible from the results of whole genome siRNA screens. 612 Bioinformatics analysis of our screening results using STRING analysis, a 613 bioinformatics application that identifies known and predicted protein-protein 614 associations (31), did not identify obvious pathways that might be involved in 615 HCMV replication (data not shown). These pathways may only reveal themselves 616 in the context of a whole genome siRNA screen. However, these approaches 617 must be applied cautiously as bioinformatics analysis may draw together protein-618 protein associations that may be the result of false-positive or false-negative 619 screening hits or that have only very modest effects on viral replication.

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

620 Previously, a screen of siRNA targeting the human kinome was conducted 621 by Terry and co-workers based in on detection of virus produced from siRNA 622 treated cells and implicated AMPK as being important in HCMV replication (8). In 623 agreement with Terry et al., we have found that treatment of infected cells with 624 the AMPK inhibitor compound C decreases accumulation of HCMV proteins and 625 production of infectious HCMV virus (data not shown). However, we observed 626 very little overlap in the identification of siRNAs that had either a positive or 627 negative effect on HCMV replication when comparing the results of Terry et al. 628 and our own. For example, in the work by Terry et al. siRNA targeting PI3K-C2A 629 had little or no effect on HCMV replication and the siRNA targets involved or 630 implicated in AMPK function during HCMV replication differ from those found in 631 our study. It is likely that differences in screening methodologies and siRNA 632 reagents reflect the differences in our data sets. It is widely accepted that 633 different siRNA reagents will display different false-positives and false-negatives 634 in different screens against the same pathogen (7, 32). To combat this issue 635 several siRNA datasets using orthologous RNAi reagents must be integrated and 636 refined to identify factors that have positive or negative effects with high certainty 637 (7, 32). Therefore, it is likely that several more siRNA datasets will have to be 638 generated before we can fully understand the effects of siRNAs on HCMV 639 replication.

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

Moreover, screening data can be further interrogated with the use of bioinformatics tools such as GESS and Haystack to eliminate off target effects of the siRNA seed sequence binding to mRNAs. However, it must be stressed that the statistical power of these analyses increases with the number of siRNAs assayed. Therefore, siRNA collections of the size used here are not often

645 assayed to find siRNA seed matches (Eugen Buehler, personal communication). 646 Thus, while the GESS and Haystack analysis used here suggests that no 647 obvious off-target binding effects occur in our screen, combining the data 648 presented here with other siRNA screening data sets may reveal as yet 649 unappreciated off-targets effects that will influence our interpretation of siRNA 650 function in HCMV infected cells.

651 Furthermore, several of the targets of siRNA in our screening data were 652 not found in a proteomic study of HFF cells infected with HCMV (27). Therefore, 653 analysis of siRNA off-target binding alone may not be sufficient to exclude 654 siRNAs from analysis. Indeed, analysis of siRNA screening data can include 655 comparison of screening hits with gene expression profiles to identify false 656 positives (7). Further analysis of siRNA screening data from HCMV infected cells 657 should benefit from comparison of siRNA screening hits with proteins known to 658 be expressed in HCMV infected cells (27), as we have preformed here. It 659 remains unknown that RNAs are targeted by the siRNAs that we judge to be 660 false positives in our screening data. Further analysis of this question should 661 identify viral or cellular RNA transcripts involved in HCMV replication.

We chose to focus our study on the involvement of PI3K-C2A in HCMV replication. The role of a least one class I and class III PI3K protein has been investigated (12, 13), however, the role of class II PI3K proteins in HCMV replication is unknown. PI3K-C2A is found in endosomes, the trans-golgi network and clathrin-coated vesicles (33, 34). Like other PI3K proteins, PI3K-C2A phosphorylates PtdIns at the D3 position of the inositol ring producing 3-

668 phosphorylated PtdIns (PtdIns3P), lipids involved membrane specification and 669 dynamics (33-36). Other phosphorylated lipids involved in membrane trafficking 670 can be produced by this lipid kinase (37). PI3K-C2A and the phosphorylated 671 lipids it produces are associated with a number of processes that involve 672 intracellular membranes including exocytosis, endocytosis, and autophagy (33, 673 34, 38), although the function of PtdIns3P produced by PI3K-C2A is largely 674 unclear. Also, PI3K-C2A can be found in the nucleus where it appears to 675 associate with cellular RNA splicing factors (39, 40).

676 Our observations point to a role for PI3K-C2A in the production of HCMV 677 virions at a step after secondary envelopment of capsids. HCMV secondary 678 envelopment is very poorly defined and our understanding of this process largely 679 relies on observations made using related viruses such as herpes simplex virus. 680 Briefly, secondary envelopment occurs upon budding of capsids into cytoplasmic 681 membranes related to the Golgi (including cis-Golgi, trans-Golgi network and 682 endosomes) and is associated with changes in cytoplasmic membranes that 683 occur during development of viral assembly compartments (2, 41). PI3K-C2A is 684 known to be enriched in the aforementioned cytoplasmic membranes (33, 34, 685 38), and in preliminary immnoflorescence experiments we observe PI3K-C2A in 686 the cytoplasm of HCMV infected cells (data not shown). Therefore, it is plausible 687 that PI3K-C2A could be associated with secondary envelopment. Furthermore, 688 PI3K-C2A is reported to be involved in exocytosis (33, 34, 38), which is thought 689 to be involved in movement of enveloped herpesvirus particles to the plasma 690 membrane (41). Therefore, we suggest that PI3K-C2A functions in exocytosis in

691 HCMV infected cells, possibly linking the completion of secondary envelopment 692 with virion egress. Interestingly, in HCMV infected cells the function of Class III 693 PI3K protein Vps34 appears to be separable from PI3K-C2A as these proteins 694 are required for processes before and after secondary envelopment, respectively 695 (13). A further point to consider is our observation that intracellular virus that 696 accumulates in infected cells treated with PI3K-C2A may not be infectious. This 697 would imply that the secondary envelopment of capsids we observe in cells 698 depleted of PI3K-C2A is somehow defective or that there are further, as yet 699 unrecognized, functions of PI3K-C2A that are required for the production of 700 infectious virus.

It is worth considering whether PI3K-C2A might be a future anti-HCMV drug target. To our knowledge there is currently no compound that potently and specifically inhibits PI3K-C2A function, or the function of any other class II PI3K protein. Also, it has been reported that well characterized inhibitors of class I PI3K proteins, wortmannin and LY294002, have little or no effect on PI3K-C2A function (42). Therefore, an original approach is required to discover inhibitors of PI3K-C2A. Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

709 ACKNOWLEDGMENTS

710

711 We would like to express our thanks to Richard Bethell and Peter Seither of 712 Boehringer Ingelheim for their great advice and support of this project. Thanks to 713 members of the Coen and Strang laboratories, especially Jean Pesola for 714 assistance with statistical and PCR analyses. Our thanks also go to Ken Laing 715 and Eugen Buehler for support with qPCR and siRNA binding analysis, to several 716 colleagues (Jeremy Kamil, Wade Gibson, Nathanael Gray, NIH AIDS Reagent 717 Program, Richard Stanton) for the kind gifts of reagents and to Laura Hudson 718 and Lisa Rickelton for assistance in the preparation of figures and tables. We 719 also acknowledge Maria Ericsson and the staff of the Harvard Medical School 720 Electron Microscope Facility for all their invaluable assistance. Special thanks go 721 to all members of Institute of Chemistry and Chemical Biology-Longwood at 722 Harvard Medical School for all of their help with all aspects of the screening 723 process.

- 724
- 725 726
- 727
- 728
- 729
- 730
- 731

<u>Journal</u> of Virology

732 FUNDING INFORMATION

733

734 This work was supported by a Boehringer Ingelheim RNAi Screening 735 Collaboration between Boehringer Ingelheim and Harvard Medical School award 736 to B.L.S. and D.M.C., grants from the National Institutes of Health to D.M.C. (R01 737 AI019838 and R01 AI026077), a studentship from the Kingdom of Saudi Arabia 738 (H.F.M.), plus New Investigator funds from St George's, University of London, a 739 St George's Impact & Innovation Award and a PARK/WestFocus Award (all to 740 B.L.S.). The funders had no role in data collection, interpretation or the decision 741 to submit the work for publication.

 \geq

Journal of Virology

Journal of Virology

742 **REFERENCES**

- 743
- Mocarski, E. S., T. Shenk, P. D. Griffiths, and R. F. Pass. 2015.
 Cytomegaloviruses p. 1960-2015. *In* D. M. Knipe and P. M. Howley (ed.),
 Fields Virology, 6th ed, vol. 2. Lippincott, Williams & Wilkins, New York,
 NY.
- Alwine, J. C. 2012. The human cytomegalovirus assembly compartment:
 a masterpiece of viral manipulation of cellular processes that facilitates
 assembly and egress. PLoS pathogens 8:e1002878.
- Brass, A. L., D. M. Dykxhoorn, Y. Benita, N. Yan, A. Engelman, R. J.
 Xavier, J. Lieberman, and S. J. Elledge. 2008. Identification of host
 proteins required for HIV infection through a functional genomic screen.
 Science (New York, N.Y 319:921-926.
- Brass, A. L., I. C. Huang, Y. Benita, S. P. John, M. N. Krishnan, E. M.
 Feeley, B. J. Ryan, J. L. Weyer, L. van der Weyden, E. Fikrig, D. J.
 Adams, R. J. Xavier, M. Farzan, and S. J. Elledge. 2009. The IFITM
 proteins mediate cellular resistance to influenza A H1N1 virus, West Nile
 virus, and dengue virus. Cell 139:1243-1254.
- Krishnan, M. N., A. Ng, B. Sukumaran, F. D. Gilfoy, P. D. Uchil, H.
 Sultana, A. L. Brass, R. Adametz, M. Tsui, F. Qian, R. R. Montgomery,
 S. Lev, P. W. Mason, R. A. Koski, S. J. Elledge, R. J. Xavier, H.
 Agaisse, and E. Fikrig. 2008. RNA interference screen for human genes
 associated with West Nile virus infection. Nature 455:242-245.

765	6.	Li, Q., A. L. Brass, A. Ng, Z. Hu, R. J. Xavier, T. J. Liang, and S. J.
766		Elledge. 2009. A genome-wide genetic screen for host factors required for
767		hepatitis C virus propagation. Proc Natl Acad Sci U S A 106: 16410-16415.
768	7.	Zhu, J., T. Davoli, J. M. Perriera, C. R. Chin, G. D. Gaiha, S. P. John, F.
769		D. Sigiollot, G. Gao, Q. Xu, H. Qu, T. Pertel, J. S. Sims, J. A. Smith, R.
770		E. Baker, L. Maranda, A. Ng, S. J. Elledge, and A. L. Brass. 2014.
771		Comprehensive identification of host modulators of HIV-1 replication using
772		multiple orthologous RNAi reagents. Cell reports 9:752-766.
773	8.	Terry, L. J., L. Vastag, J. D. Rabinowitz, and T. Shenk. 2012. Human
774		kinome profiling identifies a requirement for AMP-activated protein kinase
775		during human cytomegalovirus infection. Proc Natl Acad Sci U S A
776		109: 3071-3076.

777 9. Koyuncu, E., J. G. Purdy, J. D. Rabinowitz, and T. Shenk. 2013.
778 Saturated very long chain fatty acids are required for the production of
779 infectious human cytomegalovirus progeny. PLoS pathogens 9:e1003333.

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

Rodems, S. M., and D. H. Spector. 1998. Extracellular signal-regulated
kinase activity is sustained early during human cytomegalovirus infection.
J Virol 72:9173-9180.

Johnson, R. A., S. M. Huong, and E. S. Huang. 2000. Activation of the
mitogen-activated protein kinase p38 by human cytomegalovirus infection
through two distinct pathways: a novel mechanism for activation of p38. J
Virol 74:1158-1167.

- Johnson, R. A., X. Wang, X. L. Ma, S. M. Huong, and E. S. Huang.
 2001. Human cytomegalovirus up-regulates the phosphatidylinositol 3kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication
 and virus-induced signaling. J Virol **75**:6022-6032.
 - 13. Sharon-Friling, R., and T. Shenk. 2014. Human cytomegalovirus
 pUL37x1-induced calcium flux activates PKCalpha, inducing altered cell
 shape and accumulation of cytoplasmic vesicles. Proc Natl Acad Sci U S
 A 111:E1140-1148.
 - 14. Stanton, R. J., K. Baluchova, D. J. Dargan, C. Cunningham, O.
 Sheehy, S. Seirafian, B. P. McSharry, M. L. Neale, J. A. Davies, P.
 Tomasec, A. J. Davison, and G. W. Wilkinson. 2010. Reconstruction of
 the complete human cytomegalovirus genome in a BAC reveals RL13 to
 be a potent inhibitor of replication. The Journal of clinical investigation
 120:3191-3208.
 - Birmingham, A., L. M. Selfors, T. Forster, D. Wrobel, C. J. Kennedy, E.
 Shanks, J. Santoyo-Lopez, D. J. Dunican, A. Long, D. Kelleher, Q.
 Smith, R. L. Beijersbergen, P. Ghazal, and C. E. Shamu. 2009.
 Statistical methods for analysis of high-throughput RNA interference
 screens. Nature methods 6:569-575.
 - 806 16. Zhang, J. H., T. D. Chung, and K. R. Oldenburg. 1999. A Simple
 807 Statistical Parameter for Use in Evaluation and Validation of High
 808 Throughput Screening Assays. Journal of biomolecular screening 4:67-73.

- 831 UL97, not protein kinase C, for disruption of nuclear lamina and nuclear
 832 egress in infected cells. J Virol 88:249-262.
 - Birmingham, A., E. M. Anderson, A. Reynolds, D. Ilsley-Tyree, D.
 Leake, Y. Fedorov, S. Baskerville, E. Maksimova, K. Robinson, J.
 Karpilow, W. S. Marshall, and A. Khvorova. 2006. 3' UTR seed
 matches, but not overall identity, are associated with RNAi off-targets.
 Nature methods 3:199-204.
 - 838 25. Ma, Y., A. Creanga, L. Lum, and P. A. Beachy. 2006. Prevalence of off839 target effects in Drosophila RNA interference screens. Nature 443:359840 363.
 - Franceschini, A., R. Meier, A. Casanova, S. Kreibich, N. Daga, D.
 Andritschke, S. Dilling, P. Ramo, M. Emmenlauer, A. Kaufmann, R.
 Conde-Alvarez, S. H. Low, L. Pelkmans, A. Helenius, W. D. Hardt, C.
 Dehio, and C. von Mering. 2014. Specific inhibition of diverse pathogens
 in human cells by synthetic microRNA-like oligonucleotides inferred from
 RNAi screens. Proc Natl Acad Sci U S A 111:4548-4553.

Weekes, M. P., P. Tomasec, E. L. Huttlin, C. A. Fielding, D. Nusinow,
R. J. Stanton, E. C. Wang, R. Aicheler, I. Murrell, G. W. Wilkinson, P.
J. Lehner, and S. P. Gygi. 2014. Quantitative temporal viromics: an
approach to investigate host-pathogen interaction. Cell 157:1460-1472.

Azzeh, M., A. Honigman, A. Taraboulos, A. Rouvinski, and D. G. Wolf.
2006. Structural changes in human cytomegalovirus cytoplasmic
assembly sites in the absence of UL97 kinase activity. Virology 354:69-79.

Journal of Virology

854	29.	Sullivan, V., C. L. Talarico, S. C. Stanat, M. Davis, D. M. Coen, and K.
855		K. Biron. 1992. A protein kinase homologue controls phosphorylation of
856		ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
857	30.	Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith,
858		3rd, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife,
859		S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002.
860		Potent and selective inhibition of human cytomegalovirus replication by
861		1263W94, a benzimidazole L-riboside with a unique mode of action.
862		Antimicrobial agents and chemotherapy 46:2365-2372.
863	31.	Franceschini, A., D. Szklarczyk, S. Frankild, M. Kuhn, M. Simonovic,
864		A. Roth, J. Lin, P. Minguez, P. Bork, C. von Mering, and L. J. Jensen.
865		2013. STRING v9.1: protein-protein interaction networks, with increased
866		coverage and integration. Nucleic Acids Res 41:D808-815.
867	32.	Tripathi, S., M. O. Pohl, Y. Zhou, A. Rodriguez-Frandsen, G. Wang, D.
868		A. Stein, H. M. Moulton, P. DeJesus, J. Che, L. C. Mulder, E. Yanguez,
869		D. Andenmatten, L. Pache, B. Manicassamy, R. A. Albrecht, M. G.
870		Gonzalez, Q. Nguyen, A. Brass, S. Elledge, M. White, S. Shapira, N.
871		Hacohen, A. Karlas, T. F. Meyer, M. Shales, A. Gatorano, J. R.
872		Johnson, G. Jang, T. Johnson, E. Verschueren, D. Sanders, N.
873		Krogan, M. Shaw, R. Konig, S. Stertz, A. Garcia-Sastre, and S. K.
874		Chanda. 2015. Meta- and Orthogonal Integration of Influenza "OMICs"
875		Data Defines a Role for UBR4 in Virus Budding. Cell host & microbe
876		18: 723-735.

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

- 877 33. Falasca, M., and T. Maffucci. 2012. Regulation and cellular functions of 878 class II phosphoinositide 3-kinases. The Biochemical journal 443:587-601. 879 34. Mazza, S., and T. Maffucci. 2011. Class II phosphoinositide 3-kinase 880 C2alpha: what we learned so far. International journal of biochemistry and 881 molecular biology 2:168-182. Di Paolo, G., and P. De Camilli. 2006. Phosphoinositides in cell 882 35. 883 regulation and membrane dynamics. Nature 443:651-657. 884 36. Jean, S., and A. A. Kiger. 2012. Coordination between RAB GTPase and 885 phosphoinositide regulation and functions. Nature reviews 13:463-470. 886 37. Posor, Y., M. Eichhorn-Gruenig, D. Puchkov, J. Schoneberg, A. 887 Ullrich, A. Lampe, R. Muller, S. Zarbakhsh, F. Gulluni, E. Hirsch, M. 888 Krauss, C. Schultz, J. Schmoranzer, F. Noe, and V. Haucke. 2013. 889 Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-890 bisphosphate. Nature 499:233-237. 891 Devereaux, K., C. Dall'Armi, A. Alcazar-Roman, Y. Ogasawara, X. 38. 892 Zhou, F. Wang, A. Yamamoto, P. De Camilli, and G. Di Paolo. 2013. 893 Regulation of mammalian autophagy by class II and III PI 3-kinases 894 through PI3P synthesis. PloS one 8:e76405. 895 Didichenko, S. A., C. M. Fragoso, and M. Thelen. 2003. Mitotic and 39. 896 stress-induced phosphorylation of HsPI3K-C2alpha targets the protein for
 - 897 degradation. J Biol Chem **278:**26055-26064.

898	40.	Didichenko, S. A., and M. Thelen. 2001. Phosphatidylinositol 3-kinase
899		c2alpha contains a nuclear localization sequence and associates with
900		nuclear speckles. J Biol Chem 276:48135-48142.
901	41.	Johnson, D. C., and J. D. Baines. 2011. Herpesviruses remodel host
902		membranes for virus egress. Nature reviews. Microbiology 9:382-394.
903	42.	Maffucci, T., A. Brancaccio, E. Piccolo, R. C. Stein, and M. Falasca.
904		2003. Insulin induces phosphatidylinositol-3-phosphate formation through
905		TC10 activation. EMBO J 22:4178-4189.
906		

- 907
- 908

909 FIGURE LEGENDS

910

911 Figure 1 High throughput screening of siRNA. (A) Diagram of high throughput 912 screening process. (B) A representative example of a microscopy image from an 913 Image Express Micro microscope of HFF cells treated with Ctrl siRNA and 914 infected with AD169. Cells were then treated with Hoecsht 33342 (blue), Deep 915 Red Cell Mask (Red) and primary and secondary antibodies to detect HCMV 916 pp28 (green). The large white box is an enlarged image of the area identified in 917 the small white box. (C) z-scores from the siRNA screen. Each data point that 918 represents the z-score for PI3K-C2A siRNA is indicated. A full list of siRNAs with 919 z-scores is shown in Table S1.

920

921 Figure 2 Analysis of individual PI3K-C2A siRNAs. (A and B) HFF were treated 922 with siRNA and infected, then analyzed by automated microscopy. The number 923 of (A) cells treated with siRNA (no. of Hoecsht 33342 positive cells) and (B) the 924 percentage of those cells that are pp28 positive are shown. The mean and 925 standard deviation of each data from 4 wells treated with siRNA are shown. The 926 values above horizontal black bars in each Figure indicate the p-value derived 927 from a two-tailed (unpaired) students t-test calculated using PRISM software 928 (**=p less than or equal to 0.05, ns= no statistical difference).

929

930 Figure 3 Production of HCMV from cells treated with PI3K-C2A siRNA. HFF

931 cells were treated with Ctrl, PI3K-C2A siRNA or siRNAs PI3KC2A-1 to -4 and

Journal of Virology

932 infected with HCMV. (A and B) At the time points indicated in the figure (hours 933 post infection (h.p.i.)) viral supernatant was harvested and lysates were prepared 934 935 936 937 938 939

for western blotting from infected cells treated with PI3K-C2A siRNA. The data in Figure 3B is representative of two experiments. (C and D) Cells treated with siRNAs PI3KC2A-1 to -4 were infected with HCMV and viral supernatant was harvested at 72 h.p.i., plus uninfected cell lysate was prepared at the time of infection. In (A) and (C) proteins recognized by the antibodies used in each experiment are indicated to the right of each figure. The positions of molecular 940 weight markers (kDa) are indicated to the left of each figure. In (B) and (D) viral 941 titre is expressed at plaque forming units/ml (p.f.u./ml).

942

943 Figure 4 Western blotting of viral and cellular proteins from siRNA treated 944 cells. (A) HFF cells were treated with either Ctrl or PI3K-C2A siRNA then 945 infected with AD169. Cell lysates were prepared for western blotting at the time 946 points (hours post infection (h.p.i.)) indicated above the figure. Uninfected cells 947 harvested at the time of infection are shown as 0 h.p.i.. Panels showing signals 948 from Ctrl or PI3K-C2A siRNA treated cells are from the same exposure of the 949 same blot. (B) A 2-fold dilution series was created from samples of infected cells 950 treated with either Ctrl (C) or PI3K-C2A (P) siRNA harvested at 72 or 96 h.p.i. 951 from figure A. The siRNA and dilution factor are indicated above the figure. In 952 both figures proteins recognized by the antibodies used in each experiment are 953 indicated to the right of each figure. The positions of molecular weight markers 954 (kDa) are indicated to the left of each figure.

Journal of Virology

Z

955

Figure 5 Analysis of capsid localization and virion production. (A)-(D) 956 957 Electron microscopy analysis. HFF cells were treated with either Ctrl or PI3K-958 C2A siRNA then infected with AD169. At 96 hours post infection cells were 959 prepared for analysis by electron microcopy. Images that cover the entire area of 960 a 5 infected cells from each condition chosen at random were captured at a 961 magnification of ×9,600. The total number of A, B, and C capsids in the (A) nuclei 962 and (B) cytoplasm of infected cells were counted, as were (C) the number of C 963 capsids undergoing secondary envelopment and (D) virions leaving the cell. Thin 964 horizontal black bars indicate the mean value of each group. The values above 965 thick horizontal black bars indicate the p-value derived from a two-tailed 966 (unpaired) students t-test calculated using PRISM software (**=p<0.05, ns= no 967 statistical difference). (E)(i) Examples of capsids undergoing secondary 968 envelopment (indicated by white arrows) in a PI3K-C2A siRNA treated cell. (ii) A 969 virion leaving a cell treated with Ctrl siRNA. (F) Western blotting of viral proteins 970 in supernatant of infected cells treated with siRNA. HFF cells were treated with 971 either Crtl or PI3K-C2A siRNA and infected with AD169. Cell supernatant was 972 collected at 96 hours post infection. Supernatant was clarified with low speed 973 centrifugation, then virions were pelleted by ultracentrifugation. Pelleted virions were treated with trypsin at 4°C or 37°C and prepared for western blotting. 974 975 Proteins recognized by the antibodies used in each experiment are indicated to 976 the right of each figure. The positions of molecular weight markers (kDa) are

Accepted Manuscript Posted Online

Journal of Virology

977	indicated to the left of the figure. A non-specific band recognized by the gB
978	antibody is marked with an asterisk. The position of gB is indicated with an arrow.
979	

Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY









Figure 1




Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

Journal of Virology

Z








Journal of Virology


 \sum



Downloaded from http://jvi.asm.org/ on August 10, 2016 by ST GEORGE'S LIBRARY

Figure 4

Journal of Virology



 \sum